Phenotypic Approaches to Identify Inhibitors of B Cell Activation.

about

Phenotypic Approaches to Identify Inhibitors of B Cell Activation.

Item

http://www.wikidata.org/entity/Q38878317

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Phenotypic Approaches to Identify Inhibitors of B Cell Activation.

@en

type

Item

label

Phenotypic Approaches to Identify Inhibitors of B Cell Activation.

@en

prefLabel

Phenotypic Approaches to Identify Inhibitors of B Cell Activation.

@en

P1476

Phenotypic Approaches to Identify Inhibitors of B Cell Activation.

@en

P2093

Daniel DiSepio

http://www.w3.org/2001/XMLSchema#string

Elizabeth B Rex

http://www.w3.org/2001/XMLSchema#string

Jake Wiener

http://www.w3.org/2001/XMLSchema#string

Marcos E Milla

http://www.w3.org/2001/XMLSchema#string

Navin L Rao

http://www.w3.org/2001/XMLSchema#string

Suzie Kim

http://www.w3.org/2001/XMLSchema#string

P2860

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures

Molecular and biological characterization of a murine ligand for CD40

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents

Adhesion receptors of the immune system

Anti-IgM induces up-regulation and tyrosine-phosphorylation of heterogeneous nuclear ribonucleoprotein K proteins (hnRNP K) in a Ramos B cell line.

The SH3 domain of Bruton's tyrosine kinase displays altered ligand binding properties when auto-phosphorylated in vitro.

A FLIPR-based assay to assess potency and selectivity of inhibitors of the TEC family kinases Btk and Itk.

Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.

P304

876-886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1087057115585724

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276069235

http://www.w3.org/2001/XMLSchema#string

P698

25948491

http://www.w3.org/2001/XMLSchema#string

P932

4512518

http://www.w3.org/2001/XMLSchema#string